In terms of chemotherapeutic susceptibility, although direct associations between SLAMF1 levels and drug sensitivity in B-CLL were elusive, there is documentation indicating that an elevated mRNA expression of the mSLAMF1 isoform correlates with fludarabine sensitivity and cyclophosphamide resistance. Here, SLAMF1 is linked to B-cell chronic lymphocytic leukemia.